All case studies

Highlights

We focus our innovation on the factors that matter most — accelerating time to market, reducing costs and enhancing quality. Learn more about how we've helped clients meet and exceed their goals in this selected library of case studies.

Proactive patient retention strategy in a GLP-1 RA trial

Explore how ICON successfully supported a sponsor’s cardiovascular outcome trial for a GLP-1 receptor agonist with 9,900+ patients with type 2 diabetes and maintained a retention rate of 97% over 7 years.

A small biotech success story

A small US-based biotech company was in a race to be the first to market with their lead targeted oncology product.

FSP partnership - sustained efficiency and ongoing innovation

The implementation of an FSP model across our partner's project management function, led to 20% cost efficiences and a 30% reduction in client burden.

By taking a site and patient-centric approach, and leveraging advanced tools and real-time data insights, we maximise patient access, recruitment, and retention—ensuring that every trial is conducted with efficiency, agility, and a commitment to improving patient outcomes.

All case studies

Filter our case studies by categories, selecting amongst our broad range of solutions.

Use of Real World Data to fulfil post-approval requirements

A large pharma company submitted a New Drug Application for a targeted therapy treating a rare tumour subtype. To support safe use, a companion diagnostic PMA was filed in parallel with the FDA’s CDRH.

Custom FSP+ model drives sponsor success

A Top 10 biopharma company aimed to expand trials across CEE, including new markets. ICON delivered a custom model combining full operational ownership with local expertise and embedded governance to ensure consistency in a global, multi-vendor FSP setup.

Overcoming time zone and knowledge gaps to gain FDA IND study approval

A Europe-based biotech preparing for a phase 1/2a oncology trial turned to ICON for support during their first IND submission. With limited FDA experience, they relied on ICON to navigate the 30-day review period and respond quickly to agency requests.

Seamless transition to Functional Service Provider for medical writing

Outsourcing to an FSP often raises concerns about control, visibility, and quality. When a top-20 pharma company partnered with ICON for medical writing, ICON’s tailored approach ensured a smooth transition without sacrificing oversight or standards—building a strong, lasting partnership.

CMC and local regulatory expertise deliver timely anti-cancer drug approval

An international biopharmaceutical company based in the EU contracted ICON to support a new biologic drug application in Canada for an anti-cancer therapy for diffuse large B-cell lymphoma (DLBCL) under advance consideration.

Overcoming enrollment challenges in an early phase obesity trial

A leading multinational pharmaceutical company partnered with ICON to conduct a phase 1 obesity study assessing the safety and tolerability of a new investigational oral amycretin therapy.

Complex phase 1 obesity study

ICON was once again selected as a partner to conduct a phase 1 study in individuals who are overweight or have obesity, evaluating the safety and tolerability of a new subcutaneous GLP-1 and amylin peptide formulation.

Enabling privacy-safe, high-performing digital campaign targeting

Symphony Health, part of ICON plc, partnered with Butler/Till to boost a pharma client’s digital media strategy. Using advanced data and targeting, they improved reach and cut costs per diagnosed patient.

Affiliate level solution

A mid-size pharmaceutical company with numerous affiliates and local vendors across 80 countries sought a reliable partner for effective Pharmacovigilance (PV) and Medical Information (MI) services.

Extensive patient access and recruitment strategies

A large pharmaceutical company was conducting a Phase 2 study for adults with a BMI of 18-32. They contracted 60 US sites, including 9 Accellacare sites to recruit for two cohorts and conduct the study.

Eliminating enrolment delays to bring an AI-enabled SaMD to market

A medical device developer faced clinical evaluation timeline delays due to under-enrolment. Discover how the collaborative partnership between the sponsor and ICON’s Medical Device & Diagnostics Research team steered the study from patient enrolment to FDA submission and approval.

Optimising site selection in a rescue study

A pharmaceutical sponsor launched a global trial for elderly UTI patients, opening 125 sites across 15 countries. Enrolment lagged at 1 patient per site per month, with 70% non-enrolling. ICON was brought in to rescue the study.

Solutions case studies

Our solutions span the entire lifecycle of product development and can be adapted to suit small local trials or large global programs. Explore our work in the different aspects of our solutions.

Let's collaborate

Discover how ICON's expertise transforms clinical trials.

Blogs

Stay informed with ICON's expert insights on clinical trials, regulatory changes, and industry trends. Our blogs provide practical advice, innovative solutions, and thought leadership from global experts.

News

Stay updated with our latest news on partnerships, financial results, technological advancements, and industry insights.

Insights

Explore ICON's expert analysis and practical advice on the latest operational, regulatory, technological and economic challenges in clinical research. Our insights provide thought leadership and innovative solutions to transform trials.

Case studies

Highlights

Proactive patient retention strategy in a GLP-1 RA trial

A small biotech success story

FSP partnership - sustained efficiency and ongoing innovation

All case studies

Use of Real World Data to fulfil post-approval requirements

Custom FSP+ model drives sponsor success

Overcoming time zone and knowledge gaps to gain FDA IND study approval

Seamless transition to Functional Service Provider for medical writing

CMC and local regulatory expertise deliver timely anti-cancer drug approval

Overcoming enrollment challenges in an early phase obesity trial

Complex phase 1 obesity study

Enabling privacy-safe, high-performing digital campaign targeting

Affiliate level solution

Extensive patient access and recruitment strategies

Eliminating enrolment delays to bring an AI-enabled SaMD to market

Optimising site selection in a rescue study

Solutions case studies

Let's collaborate

Blogs

News

Insights